Clinical trial
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic…
NCT00003091 · Hoag Memorial Hospital Presbyterian, Other · Completed
Key facts
| NCT number | NCT00003091 |
|---|---|
| Title | High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma |
| Official title | Treatment of Metastatic Renal Cell Carcinoma and Melanoma With Subsequential High-Dose Subcutaneous Interferon Alfa-2b and High-Dose Bolus and Continuous Intravenous Interleukin-2 |
| Lead sponsor | Hoag Memorial Hospital Presbyterian, Other |
| Collaborators | Cancer Biotherapy Research Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, recombinant interferon alfa |
| Enrollment | 40 |
| Start date | Jan 1, 1996 |
| Primary completion | Jan 1, 2000 |
| Completion | Jan 1, 2000 |
| First posted | Jul 7, 2004 |
| Last update posted | May 12, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: